Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Opdivo Secures India Patent, Fends Off Multi-Party Opposition

Useful Indicator Of Interpretation?

Executive Summary

India clears Opdivo patent, turning down pre-grant representations from four opposing parties including Dr Reddy's. The patent office rejected the opponents' arguments including those around obviousness and "inherent anticipation."

You may also be interested in...



IQVIA Exec On Putting India Firmly In IO Trials Reckoning

An IQVIA executive in Asia sees scope for India to figure routinely on the radar of sponsors for immuno-oncology trials and outlines how some gaps to get there can be plugged.

Will Keytruda Price Differential Really Count In India?

Merck has launched Keytruda at an “India-specific” price but some experts say that the immuno-oncology therapy will likely still be beyond the reach of a majority of patients. Merck though also expects to offer a patient access program for those who can’t afford the therapy.

Patent Settlement Offers Some Salve For Bristol’s PD-1 Wounds

Bristol-Myers Squibb has taken a beating over setbacks for its Opdivo and its immuno-oncology portfolio, but a settlement reached with Merck over Keytruda’s patent infringement is a momentary victory for the PD-1 pioneer.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC142539

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel